Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI083117-01
Agency Tracking Number: AI083117
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solitcitation Year: 2009
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2009-2
Small Business Information
WASATCH MICROFLUIDICS
4909 BROWN VILLA COVE, SALT LAKE CITY, UT, 84123
Duns: 171205177
Hubzone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 BRUCE GALE
 (801) 585-5944
 BRUCE.GALE@UTAH.EDU
Business Contact
 JOSH ECKMAN
Phone: (801) 792-7074
Email: bruce@microfl.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a multiplex label free platform for high-throughput HIV specific serum antibody detection of patient samples. To help Wasatch Microfludics reach this ultimate goal, this proposal will address the feasibility of performing high throughput label free detection of serum antibodies to a variety of HIV proteins through the application of a novel microfluidic spotting technology to available Surface Plasmon Resonance (SPR) array platforms. Specifically, a microfluidic flow cell array will be adapted for work with real world samples such as plasma, serum, and cell lysates. The flow cell array will have 48 channels and address an array of spots designed to support ongoing pre- clinical trials in non-human primates as well as HIV vaccine trials in humans. The development of a low cost, high throughput, multiplex assay to assess the development of humoral immune responses following vaccine administration is essential for comprehensive immunomonitoring. PUBLIC HEALTH RELEVANCE: The successful completion of this proposal will create a dramatic improvement in the ability to conduct multiplex SPR-based assays in drug discovery and proteomic research. On a greater scale, this will lead to improved diagnostic tools and reductions in the cost and time of drug development, by significantly improving the throughput of label free screening.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government